{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Campo I"],"funding":["Boehringer Ingelheim"],"pubmed_abstract":["Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disorder involving production of autoantibodies against endogenous granulocyte-macrophage colony-stimulating factor (GM-CSF). This study aimed to identify biomarkers that could be used to monitor for aPAP, particularly in patients treated with anti-GM-CSF antibodies. This was an exploratory, prospective, observational, single-center study. Pre-specified biomarkers were evaluated between baseline and Day 120 in serum/plasma, whole blood, sputum and exhaled breath condensate from patients with aPAP, healthy volunteers, and patients with chronic obstructive pulmonary disease (COPD) and asthma (not treated with anti-GM-CSF and with no evidence of aPAP). Pulmonary function tests were also performed. Overall, 144 individuals were en"],"journal":["Scientific reports"],"pagination":["8708"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9130212"],"repository":["biostudies-literature"],"pubmed_title":["An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP)."],"pmcid":["PMC9130212"],"pubmed_authors":["Gupta A","Gahlemann M","Ittrich C","Sauter W","Trapnell BC","Meloni F","Schoelch C","Campo I"],"additional_accession":[]},"is_claimable":false,"name":"An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP).","description":"Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disorder involving production of autoantibodies against endogenous granulocyte-macrophage colony-stimulating factor (GM-CSF). This study aimed to identify biomarkers that could be used to monitor for aPAP, particularly in patients treated with anti-GM-CSF antibodies. This was an exploratory, prospective, observational, single-center study. Pre-specified biomarkers were evaluated between baseline and Day 120 in serum/plasma, whole blood, sputum and exhaled breath condensate from patients with aPAP, healthy volunteers, and patients with chronic obstructive pulmonary disease (COPD) and asthma (not treated with anti-GM-CSF and with no evidence of aPAP). Pulmonary function tests were also performed. Overall, 144 individuals were en","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-09T18:56:20.475Z","creation":"2025-04-05T20:39:51.993Z"},"accession":"S-EPMC9130212","cross_references":{"pubmed":["35610268"],"doi":["10.1038/s41598-022-11446-8"]}}